Carlos A. Parra
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Carlos A. Parra
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Telik, Inc.
Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA.
11
| Extinct | Pharmaceuticals: Major | 11 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Carlos A. Parra tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
ALZA CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
PHARMACYCLICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
INTERMUNE INC | Biotechnology | Director/Board Member Corporate Officer/Principal | |
ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
DURECT CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Pharmaceuticals: Other | Director/Board Member | |
MARINUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Pharmaceuticals: Major | Director/Board Member | |
NextWave Pharmaceuticals, Inc.
NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chief Executive Officer | |
Bullet Biotechnology, Inc.
Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | Biotechnology | Director/Board Member | |
BioMotiv LLC
BioMotiv LLC BiotechnologyHealth Technology BioMotiv LLC operates as a research institution in the field of therapeutics. It focuses in disease areas and classes of therapeutics such as small molecules, antibodies, proteins, and nucleotides. The company was founded on September 10, 2012 and is headquartered in Cleveland, OH. | Biotechnology | Director/Board Member | |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Director/Board Member | |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Corporate Officer/Principal | |
University of Bath | College/University | Undergraduate Degree | |
San Jose State University | College/University | Undergraduate Degree | |
Santa Clara University | College/University | Director/Board Member | |
University of Arizona | College/University | Undergraduate Degree | |
University of California, Davis | College/University | Graduate Degree Undergraduate Degree | |
University of Phoenix | College/University | Masters Business Admin | |
INOVIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Ilypsa, Inc.
Ilypsa, Inc. BiotechnologyHealth Technology Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA. | Biotechnology | Chief Executive Officer | |
University College London | College/University | Doctorate Degree | |
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Investment Managers | Chief Executive Officer | |
D&R Products Co., Inc.
D&R Products Co., Inc. Medical SpecialtiesHealth Technology D & R Products Co., Inc. is a contract manufacturing private company for medical devices with over 38 years of experience. The company is based in Hudson, MA. The company is an FDA registered outsource partner that specializes in producing nitinol medical devices, CNC machining, engineering, welding, and secondary operations. Richard B. Newman has been the CEO of the company since 1983. | Medical Specialties | Chief Executive Officer | |
Christopher & Dana Reeve Foundation | Investment Trusts/Mutual Funds | Chairman | |
Syntex Laboratories, Inc. | Corporate Officer/Principal | ||
RELYPSA INC | Pharmaceuticals: Major | Founder | |
ALZA Pharmaceuticals | Corporate Officer/Principal | ||
Craig Hospital
Craig Hospital Hospital/Nursing ManagementHealth Services Craig Hospital is a center for specialty rehabilitation and research for people with spinal cord injury and traumatic brain injury. The firm provides a system of inpatient and outpatient medical care, rehabilitation, neurosurgical rehabilitative care and long-term follow up services. The company was founded in 1907 and is headquartered in Denver, CO. | Hospital/Nursing Management | Director/Board Member | |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member | |
AIMMUNE THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Investment Managers | Director/Board Member | |
DJS Antibodies Ltd.
DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Biotechnology | Chairman | |
Scioto Biosciences, Inc.
Scioto Biosciences, Inc. BiotechnologyHealth Technology Scioto Biosciences, Inc. operates as a preclinical stage company. It develops therapies to transform the delivery of microbiome therapeutics. The firm?s platform enhances probiotics that are used for diabetes, neurological disorders, gastrointestinal health and alternatives to in-feed antibiotics. The company was founded by Joseph P. Trebley, Jim Schulz, Goodman Steve, Lauren O. Bakaletz, Michael Bailey and Gail E. Besner in May 2017 and is headquartered in Indianapolis, IN. | Biotechnology | Director/Board Member | |
ARAVIVE, INC. | Biotechnology | Chief Executive Officer | |
HatchBox Bioconsulting LLC
HatchBox Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services HatchBox Bioconsulting LLC provides life science advisory services. | Miscellaneous Commercial Services | Private Equity Investor | |
Alsa Management Services Ltd
Alsa Management Services Ltd Investment ManagersFinance Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Investment Officer | |
Altamont Pharma Acquisition Corp.
Altamont Pharma Acquisition Corp. Financial ConglomeratesFinance Altamont Pharma Acquisition Corp. is a blank check company. It engages in effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded on January 6, 2021 and is headquartered in Austin, TX. | Financial Conglomerates | Director/Board Member | |
Sofinnova Ventures | Corporate Officer/Principal | ||
Cessation Therapeutics, LLC
Cessation Therapeutics, LLC Pharmaceuticals: MajorHealth Technology Cessation Therapeutics, LLC is a clinical-stage pharmaceutical company that develops immunobiologics to prevent and protect against overdose. The company is based in San Jose, CA. The company's monoclonal antibodies are designed to target fentanyl and future synthetic opioids and other substances. The company has the potential to treat a range of substance use disorders and improve the lives of patients and families affected by the addiction crisis. Cessation was founded in 2018 by Mark Pearson and John D. Harkey, Jr., experienced, successful long-term biotech investors. The CEO is Mark E. Pearson. | Pharmaceuticals: Major | Director/Board Member | |
Arjuna Therapeutics
Arjuna Therapeutics Medical/Nursing ServicesHealth Services Arjuna Therapeutics is a Spanish biotechnology company that specializes in developing a new class of small molecules called therapeutic molecular clusters (TMCs) for the treatment of cancer. Arjuna Therapeutics is based in A Coruña, Spain. TMCs are biomarker-driven and selectively kill cancer cells that exhibit high levels of ROS. The company believes that their approach to treating life-threatening diseases without effective treatment options will accelerate FDA approval. The company was founded by Fernando Dominguez and Arturo López Quintela, and the CEO is Ross Breckenridge. | Medical/Nursing Services | Director/Board Member | |
Pathalys Pharma, Inc.
Pathalys Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler. | Pharmaceuticals: Major | Founder | |
BioNeex, Inc.
BioNeex, Inc. Packaged SoftwareTechnology Services BioNeex, Inc. is an American company located in Syracuse, NY, that operates as a drug development platform. It was founded by Smbat Rafayelyan and Tigran Rafayelyan. Smbat Rafayelyan has been the CEO since 2018. The company says this about itself: BioNeex is the first R&D open exchange platform in the biopharma industry, facilitating licensing and co-development partnerships for preclinical and clinical-stage drug candidates between biotech, biopharma companies and research institutions. Data posted on the drug candidate marketplace is listed by biotech, biopharma companies, and research institutions, enabling potential licensing and co-development partners as well as investors to contact them directly with one click. | Packaged Software | Director/Board Member | |
Vantage Biosciences Ltd.
Vantage Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Vantage Biosciences Ltd. develops drugs for diabetic eye disease. The British company was founded by Andre Badalyan, Katie Sunnucks, Graeme R. Martin, Alek Safarian. | Pharmaceuticals: Major | Founder |
Statistiche
Distribuzione geografica
Stati Uniti | 43 |
Regno Unito | 6 |
Austria | 2 |
Israele | 2 |
Spagna | 2 |
Settori
Health Technology | 29 |
Consumer Services | 8 |
Finance | 6 |
Health Services | 4 |
Miscellaneous | 2 |
Posizioni
Director/Board Member | 59 |
Corporate Officer/Principal | 24 |
Independent Dir/Board Member | 23 |
Undergraduate Degree | 10 |
Chief Executive Officer | 7 |
Contatti più connessi
Insiders | |
---|---|
Jay Shepard | 30 |
Mary Gray | 27 |
Graeme Martin | 15 |
Robert W. Frick | 14 |
William Phillip Kaplan | 7 |
Marc L. Steuer | 6 |
Le-Van Nguyen | 6 |
Michael K. Inouye | 5 |
Richard B. Newman | 3 |
Herwig von Morzé | 3 |
Wendy K. Wee | 3 |
- Borsa valori
- Insiders
- Carlos A. Parra
- Connessioni Società